Viral Load in Blood and Lymph Tissues in People Living With HIV
Recruiting
This is a study to determine the effect of the human immunodeficiency virus (HIV) on lymphoid tissues (e.g., lymph nodes) as compared to peripheral white blood cells. We have shown in previous studies that the lymph node is a major site of accumulation of HIV in the body, as well as being a site where much of the viral replication occurs which leads to the destruction of the body's immune system. To better understand the role of the lymph node in HIV infection and destruction of one s immunity,... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: HIV
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Recruiting
Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be s... Read More
Gender:
ALL
Ages:
Between 8 years and 65 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Major Depressive Disorder, Anxiety Disorders
Baltimore Longitudinal Study of Aging
Recruiting
Background: - The Baltimore Longitudinal Study of Aging (BLSA) is a clinical research program on human aging that began in 1958. Volunteers of different ages join the study when they are healthy, and have follow-up visits for life. Visits last for multiple days. Participants are evaluated for many physical elements as well as for brain function. Physical tests are given. Information on mood, personality, and social aspects of life is also collected. This program has contributed more than any ot... Read More
Gender:
ALL
Ages:
Between 20 years and 120 years
Trial Updated:
06/27/2025
Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland
Conditions: Aging
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Recruiting
Background: * Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and swelling of the legs. These problems can decrease or go away without treatment in about 25 percent of patients, but if they persist, some patients may experience impaired (or loss... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/27/2025
Locations: National Naval Medical Center, Bethesda, Maryland +1 locations
Conditions: Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
Recruiting
Background: - The third molars (wisdom teeth) normally grow in during late adolescence or early adulthood. Many people need or choose to have these teeth removed with oral surgery. Normally, the removed teeth and tissue are thrown away as medical waste. However, oral health researchers want to collect the teeth and tissue for research. They also want to encourage dentists at the National Institutes of Health to improve their skills in oral surgery. This study will collect the teeth and tissue o... Read More
Gender:
ALL
Ages:
Between 16 years and 50 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Stomatognatic, Tooth Diseases, Diseases, Tooth, Tooth Impaction
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
Recruiting
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.
Gender:
ALL
Ages:
All
Trial Updated:
06/27/2025
Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts
Conditions: Breast Carcinoma
Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System
Recruiting
Background: Researchers are testing version of a system known as a magnetic resonance imagining (MRI) scanner that uses strong magnetic fields, radio waves and the like to create images of the organs in the body. It uses lower energy levels than other MRI scanners. This may help scan people with metal devices in their body, or in invasive heart procedures using metal tools. Objective: To test a new MRI scanner and software changes to create better pictures. Eligibility: People with disease... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/27/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: CAD
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Recruiting
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The first primary objective is to evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \[MK-1439\] when given in combinat... Read More
Gender:
ALL
Ages:
Between 4 weeks and 11 years
Trial Updated:
06/27/2025
Locations: University of Colorado at Denver ( Site 0108), Aurora, Colorado +21 locations
Conditions: Human Immunodeficiency Virus (HIV) Infection
Conversations You Want About Corona Virus Disease (COVID-19)
Recruiting
Web-enabled virtual topical guide: develop virtual conversations for each concern and intensity level
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Wake Forest Health Sciences, Winston-Salem, North Carolina
Conditions: Covid19
A Study to Investigate the Pharmacokinetics (PK) and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
Recruiting
This is a two-part, Phase IIa, multicenter, 12-week, open-label study. Up to 56 participants with deletion AS aged 5-17 years (inclusive) will be enrolled in the study.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
06/27/2025
Locations: Rady Children's Hospital - San Diego, San Diego, California +19 locations
Conditions: Angelman Syndrome
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Recruiting
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the M... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
06/27/2025
Locations: Digestive Health Specialists ( Site 0135), Dothan, Alabama +431 locations
Conditions: Ulcerative Colitis
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Recruiting
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +180 locations
Conditions: Acute Myeloid Leukemia